Jazz Pharma has agreed to pay $145 million to settle lawsuits claiming it illegally acted to prevent generic versions of its narcolepsy therapy Xyrem from entering the US market. The lawsuits ...

Jazz Pharmaceuticals will pay $145 million to settle allegations of anti-trust practices related to its narcolepsy drug Xyrem, according to an SEC filing on Tuesday. The settlement, which is still ...

Subject to court approval, the settlement will bring an end to class action lawsuits initiated by several Xyrem buyers who accused Ireland-based Jazz (NASDAQ:JAZZ) of reaching illegal patent ...

Xyrem, a medication approved in the U.S., is used for the treatment of excessive daytime sleepiness and sudden loss of muscle control in patients suffering from narcolepsy, a chronic neurological ...

This is a practice very common among cancer drugs. Other than the reputation and infamous notoriety of the drug, Xyrem had another drawback. It contains 109% of the American Heart Association’s ...